ReviewClinical & developmental immunology2012
Blocking type I interferon production: a new therapeutic option to reduce the HIV-1-induced immune activation.
Review in Clinical & developmental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Clinical and experimental treatment of residual immune activation in people living with HIV.Clinical and experimental immunology · 2025Review
- Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine.Journal of immunology research · 2020Review
- A compartmentalized type I interferon response in the gut during chronic HIV-1 infection is associated with immunopathogenesis.AIDS (London, England) · 2018Article
- Morphine-potentiated cognitive deficits correlate to suppressed hippocampal iNOS RNA expression and an absent type 1 interferon response in LP-BM5 murine AIDS.Journal of neuroimmunology · 2018Article
- Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement.Nature communications · 2017Article
- Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients.PloS one · 2017Article
- Select host restriction factors are associated with HIV persistence during antiretroviral therapy.AIDS (London, England) · 2015Article
- Modulation of type I interferon-associated viral sensing during acute simian immunodeficiency virus infection in African green monkeys.Journal of virology · 2015Article
- Interferon-α Subtypes in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector Mechanisms.PLoS pathogens · 2015Article
- Putative roles of purinergic signaling in human immunodeficiency virus-1 infection.Biology direct · 2014Article
- Monocyte activation from interferon-α in HIV infection increases acetylated LDL uptake and ROS production.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2014Article
- Decoding the complexity of type I interferon to treat persistent viral infections.Trends in microbiology · 2013Review
- Immune quiescence: a model of protection against HIV infection.Retrovirology · 2013Review
- Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.Neuroscience · 2013Review
- Networking at the level of host immunity: immune cell interactions during persistent viral infections.Cell host & microbe · 2013Review
- Blocking TLR7- and TLR9-mediated IFN-α production by plasmacytoid dendritic cells does not diminish immune activation in early SIV infection.PLoS pathogens · 2013Article
- Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?Retrovirology · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Highly active antiretroviral therapy has dramatically improved the morbidity and mortality of HIV-1-infected individuals. A total of 25 licensed drugs provide the basis for an optimized virus-suppressive treatment of nearly each subject. The promises of immune reconstitution and normal life expectancy, however, fall short for a number of patients, either through inadequate recovery of CD4+ T-cell counts or the occurrence of non-AIDS defining malignancies. In this respect, the prevalence of Epstein-Barr virus-associated Hodgkin lymphoma and human papillomavirus-related anal neoplasia is rising in aging HIV-1-infected individuals despite antiretroviral therapy. An important cause appears to be the HIV-1-induced chronic immune activation, propagated by inappropriate release of proinflammatory cytokines and type I interferons. This immune dysregulation can be reduced in vitro by inhibitors blocking the endosomal acidification. Recent data suggest that this concept is also of relevance in vivo, which opens the door for adjuvant immunomodulatory therapies in HIV-1 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.